Our preliminary results suggest that isoliquiritigenin, naringenin and Gly1 fraction might serve as a potential therapeutic drug for inflammatory colitis or other autoimmune and inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis. This evidence concerns the gene THA1P and rheumatoid arthritis.